Helogen

Helogen

Autonomous orbital biology research platforms

Overview

Helogen provides autonomous, space-based biology platforms with orbital laboratories for high-throughput drug discovery and biomanufacturing. Its labs use proprietary tools—Multi-Modal Culture Analyzer, Sequencer, and Bioreactor—to grow, monitor, and manufacture biological systems in microgravity via remotely operated operations. The company differentiates itself through end-to-end space assays with commercial rights to materials from partnerships, plus notable collaborations with Memorial Sloan Kagan? Memorial Sloan Kettering and NASA, and the acquisition of Vellon Space to expand MEAP coverage, enabling faster, scalable space biology. Helogen’s goal is to make space research faster, cheaper, and more accessible to accelerate early-stage drug development, tissue engineering, and aging research.

Significant Headcount Growth

About Helogen

Simplify's Rating
Why Helogen is rated
C+
Rated C on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Robotics & Automation

Aerospace

Biotechnology

Healthcare

Company Size

11-50

Company Stage

Early VC

Total Funding

$760K

Headquarters

New York City, New York

Founded

2022

Get referred to Helogen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Starlab announced HEL-IOS™ integration on February 18, 2026.
  • Helogen's site lists HC-263 Cyrus for March 2026 and HC-264 for June 2026.
  • MSK and NASA partnerships validate oncology and sequencing use cases in orbit.

What critics are saying

  • One failed 2026 mission can halt payload credibility and revenue for months.
  • Starlab integration concentrates execution risk on Voyager Technologies and one station program.
  • SPARK Microgravity and other autonomous lab startups compress Helogen's premium pricing advantage.

What makes Helogen unique

  • HEL-IOS™ automates biology, sequencing, and analytics in orbit without crew intervention.
  • Helogen's April 2025 Vellon acquisition gives India and APAC market access.
  • Helogen combines orbital labs with commercial rights to space-made biomaterials.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$760k

Above

Industry Average

Funded Over

1 Rounds

Early VC funding comparison data is currently unavailable. We're working to provide this information soon!
Early VC Funding Comparison
Coming Soon

Benefits

Unlimited Paid Time Off

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

20%

1 year growth

20%

2 year growth

20%
GlobeNewswire
Apr 30th, 2025
Helogen Acquires Vellon Space in India

Helogen Corporation has acquired Vellon Space, a Bengaluru-based startup, to expand its reach into India's space and biotechnology sectors. The acquisition aims to leverage Vellon's expertise and collaborations with ISRO and other institutions to offer advanced orbital biomanufacturing and drug development technologies. India's pharmaceutical market, valued at $58 billion, is projected to reach $120–130 billion by 2030. The terms of the transaction remain confidential.

Recently Posted Jobs

Sign up to get curated job recommendations

Helogen is Hiring for 3 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →